Play all audios:
NEW YORK — There’s been a lot of excitement about immunotherapy as a tool to treat cancer. But as leading experts gathered here on Sunday, several struck an unexpected note of caution. “Be
critical,” said Dr. Philip Greenberg of the University of Washington, who’s also scientific cofounder of Juno Therapeutics, one of the companies leading the search for immune-based
treatments for cancer. “Don’t believe everything you hear.” Although progress toward harnessing the immune system to attack tumors has been “enormous,” he said, his lab and many others are
seeing in more and more studies — in lab mice as well as patients — that “immuno-oncology” will not be as simple as stimulating T cells to attack tumors. STAT+ Exclusive Story Already have
an account? Log in THIS ARTICLE IS EXCLUSIVE TO STAT+ SUBSCRIBERS UNLOCK THIS ARTICLE — PLUS DAILY COVERAGE AND ANALYSIS OF THE BIOTECH SECTOR — BY SUBSCRIBING TO STAT+. Already have an
account? Log in Individual plans Group plans View All Plans To read the rest of this story subscribe to STAT+. Subscribe